Jacob Antrican, Author at NFCR - Page 2 of 2

Jacob Antrican

Meet Betty Locke

Betty has been donating to the Fly to Find a Cure program for the past 8 years.bettyphoto

I’ve loved to travel since I was a little girl. Sadly, my father passed away from liver cancer when I was 12 years old. Then, my husband died in 2001 from the same type of cancer. Donating to the National Foundation for Cancer Research’s Fly to Find a Cure program makes me feel like I’m helping people everywhere, including myself. It’s always wonderful to get the extra mileage to visit the places I want to go.” says Locke.

What is Fly to Find a Cure?

Fly to Find a Cure is a program of the National Foundation for Cancer Research (NFCR) aimed at raising funds to accelerate vital cancer research. You can donate with Fly to Find a Cure and get air miles in return for your gift.

We are proud to offer earning power from American Airlines AAdvantage®, United MileagePlus®, Delta SkyMiles® and most recently, Alaska Airlines Mileage Plan®. This a great way to keep your mileage account active, and as in Betty’s case, earn airline miles to go somewhere special.


Now through October 152016 you can earn up to 50% more mileage for every dollar donated.

Your contribution, like Betty’s, will help NFCR scientists find cures for all types of cancers.  Travel the world and fund vital cancer research that saves lives. It’s a win-win. Donate TODAY at www.nfcr.org/miles or call Melissa White at 1-800-321-CURE (2873)

“Cancer is a disease that can be cured…” – Nobel Laureate and National Foundation for Cancer Reserarch Co-Founder Dr. Albert Szent-Györgyi


Award Scale: Up to 15 miles per dollar with a donation of $100 or more
Fair Market Value: $0.0241875 per mile
Mileage Cap: 1,000,000 miles per account per calendar year

Click here to donate 

american-milesAward Scale: Up to 15 miles per dollar with a donation of $100 or more
Fair Market Value: $0.022575 per mile
Mileage Cap: 1 million miles per account per rolling year

Click here to donate 

united_mileage_plus_3p_4c_r2Award Scale: Up to 13.5 miles per dollar with a donation of $100 or more
Fair Market Value: $0.028 per mile
Mileage Cap: 250,000 miles per account per rolling year

Click here to donate

delta-milesAward Scale: Up to 13 miles per dollar with a donation of $100 or more
Fair Market Value: $0.023650 per mile
Mileage Cap: 200,000 miles per account per calendar year

Click here to donate 

Read more

Get Even MORE Airline Miles Today!

Where will you be frolicking this fall?  Let our airlines miles program help you get there!

What is Fly to Find A Cure?

Fly to Find A Cure is a program of the National Foundation for Cancer Research (NFCR) aimed at raising crucial funds to accelerate vital can
cer research projects.  For every dollar donated, you earn airline mileage from your choice of Alaska Airlines Mileage Plan®, American Airlines AAdvantage®, United MileagePlus® or Delta SkyMiles®.  A major portion of your gift is tax deductible.  This is also a great way to keep an account active.  Fly to Find A Cure miles can even be given as a gift to family or friends.

What is
Fly to Find A Cure’s Fall Bonus Miles Program?

Now through October 15th, Fly to Find A Cure’s Fall Bonus Miles Program allows you to earn up to 15 miles per dollar (instead of our usual 10) while supporting groundbreaking cancer research.  This provides a win-win opportunity for travelers who care about putting an end to this dreaded disease.

Together We Can Put an End to Cancer

The statistics are staggering: 1 in 2 women and 1 in 3 men will be diagnosed with cancer in their lifetime. This means that cancer will very likely affect each and every one of us at some point in our lives — whether it is through our own personal diagnosis or through that of someone we love.   The only way to stop cancer is to cure it – through research.

Give a generous gift today to help find a cure for cancer and you’ll be that much closer to taking the trip you’ve dreamed about!

“Cancer is a disease that can be cured…” – Nobel Laureate and National Foundation for Cancer Reserarch Co-Founder Dr. Albert Szent-Györgyi

american-milesAward Scale: Up to 15 miles per dollar with a donation of $100 or more
Fair Market Value: $0.022575 per mile
Mileage Cap: 1 million miles per account per rolling year

Click here to donate 

united_mileage_plus_3p_4c_r2Award Scale: Up to 13.5 miles per dollar with a donation of $100 or more
Fair Market Value: $0.028 per mile
Mileage Cap: 250,000 miles per account per rolling year

Click here to donate

delta-milesAward Scale: Up to 13 miles per dollar with a donation of $100 or more
Fair Market Value: $0.023650 per mile
Mileage Cap: 200,000 miles per account per calendar year

Click here to donate 

Award Scale: Up to 15 miles per dollar with a donation of $100 or more
Fair Market Value: $0.0241875 per mile
Mileage Cap: 1,000,000 miles per account per calendar year

Click here to donate 

Read more

Research by NFCR Scientists Reveals New Insights into Treatment Resistance of Metastatic Breast Cancer

Oscillating expression of a key cancer gene may impact treatment approaches for patients

NFCR-supported scientist Dr. Daniel Haber and his team at the Massachusetts General Hospital Cancer Center have identified a dynamic gene expression in metastatic breast cancer that may contribute to disease progression and resistance to treatment experienced by many patients. Tumors can evolve in response to treatment and they may acquire new genetic features that may make them resistant to drugs and cause disease progression.

In their quest to find genetic changes in advanced breast cancer, the scientists utilized the rare circulating tumor cells (CTCs) found in a patient’s bloodstream – which have migrated away from a tumor and into blood vessels. CTCs offer a wealth of information to researchers and oncologists about the state of a patient’s cancer.

“I am thankful to the NFCR for their sustained support of our research to increase our understanding of the genes involved in the progression of cancer and to develop prevention and treatment strategies for metastatic cancer,” said Dr. Haber.

The Haber team used their device, the CTC-iChip, to collect viable CTCs from women initially diagnosed with primary breast tumors that are ER+/HER2-, meaning that their tumor cells expressed estrogen receptor genes (ER+) but did not express the HER2 gene (HER2–). Both ER and HER2 genes are known for their role in fueling breast cancer cells and promoting tumor growth. The patients had undergone multiple courses of treatment for recurrent metastatic cancer.

Intriguingly, molecular characterization of the isolated CTCs revealed not just ER+ / HER2– tumor cells, but also a second type: the ER+ / HER2+ cells that also express the HER2 gene.

Through a series of elegant laboratory experiments, the researchers delved deeper to characterize the CTCs and found a unique and dynamic interconversion of HER2 gene expression: ER+/HER2– cells could spontaneously become ER+/HER2+ and convert back to ER+/HER2–. In addition, researchers found that the two populations of tumor cells depended on different molecular signaling pathways for their proliferation and consequently, were sensitive to different anti-cancer drugs.

Because HER2 gene expression oscillates between on and off spontaneously in these tumors, researchers reasoned that the two separate signaling pathways may need to be simultaneously turned off to halt either cell group from repopulating one another and beginning new abnormal growth. Results of further experiments in cell cultures and more advanced tumor models proved that simultaneous treatment with chemotherapy paclitaxel and targeted therapeutic drugs that inhibit the NOTCH1 molecular signaling pathway achieved suppression of tumor cell growth expressing both ER+ / HER2– and HER2+ subpopulations.

This breakthrough discovery was published in the August 24 online edition of the journal Nature.

“Although more research is needed to uncover why HER2 has this dynamic on-and-off expression, these insights from our research are a positive development for a new treatment approach,” said Dr. Haber.

Dr. Haber also notes that clinical trials will now be needed to test whether these insights from experimental models will translate into better and more effective treatments for women with advanced breast cancer.

“The CTC research platform developed by Dr. Haber and his team continues to produce new knowledge about the intricate ways that cancer may grow and evade treatments,” said Franklin Salisbury, CEO of NFCR. “Metastatic disease causes more than 90% of the fatalities to cancer and the new insights from this research have opened the field for potential new treatment approaches so desperately needed for patients with metastatic breast cancer.”



Read more

Welcoming Alaska Airlines Mileage Plan

We are pleased to welcome Alaska Airlines Mileage Plan as the newest way to earn with Fly to Find a Cure.  Along with its Global Partners, Alaska Mileage Plan offers its members the ability to earn and redeem miles to over 800 destinations around the world.  With this new earning opportunity, you can help cancer research soar to new heights.

When you donate with Fly to Find A Cure, you receive airline miles in exchange for your support of cutting-edge cancer research funded by the National Foundation for Cancer Research (NFCR).  Here’s how it works:  Make a tax-deductible contribution of $25 or more to NFCR and receive 10 airline miles per dollar towards your Alaska Airlines Mileage Plan.

Other NFCR partners include American Airlines AAdvantage, United Airlines MileagePlus® and Delta SkyMiles® .  To learn more about Fly to Find A Cure, visit http://nfcr.org/miles/.

Take advantage of this new earning opportunity – Alaska Airlines Mileage Plan plus Fly to Find a Cure – and donate today!  Now you can earn your dream vacation and help fund the scientific breakthroughs that will save lives!

Read more

Minor League Baseball and Play4TheCure

For the second year in a row, Play4TheCure and minor league baseball are teaming up this summer to raise money and awareness for cutting-edge cancer research. The program was started by National Foundation for Cancer Research (NFCR) Youth Ambassador Ally Minker.

Inspired by the passing of her grandfather, Ally took it upon herself to motivate others and advance the cause towards a cure for cancer by involving as many baseball teams as possible. Baseball was one of her granfather’s greatest passions and he imparted that to Ally. So naturally, she turned to the community he loved so much to honor his memory.Primary_Logo_Color

This year, teams in the Carolina League as well as the Quad City River Bandits have heeded Ally’s call and committed games to the Play4TheCure mission. The growth of the program within the sport of baseball is a testament to Ally’s dedication to serving others and saving lives through cancer research.

Here’s a list of teams participating this year:

  • Wilmington Blue Rocks – 7/30/16 – 7:05 PM vs. Frederick Keys – BUY TICKETS and be sure to use promo code “PLAY” | $2 for every ticket sold will go to support cancer research
  • Quad Cities River Bandits (Davenport, IA) – 8/7/16 – 1:15 PM vs. Burlington Bees
  • Ft. Myers Miracles – 8/11/16 – 7:05 PM – vs. Charlotte Stone Crabs
  • Frederick Keys – 8/16/16 – 6:00 PM – vs. Lynchburg Hillcats
  • Charlotte (FL) Stone Crabs – 8/20/16 – 6:05 PM – vs. Bradenton Marauders
  • Tampa Yankees – 8/27/16 – 6:35 PM – vs. Brevard County Manatees
Read more

Be Like Amos – Our 9 Year Old Philanthropist

The NFCR staff was touched by this very special donation. Read his story and share it freely with others. It made our day and we hope it makes yours as well. Meet Amos, our now famous, 9 year old Philanthropist:

photo of Amos. Our 9 year old philanthropist Amos_Porter

From left to right: Arlo (5), Amos (9), and Phil

Less than one year ago, Amos’ father, Phil, experienced a sore throat and noticed a spot on the back of his throat. Phil went to see his general practitioner as well as an ENT doctor who made the diagnosis, tonsillar cancer.  Phil received extraordinary treatment from his surgical team at UPENN followed by thirty treatments of proton radiation therapy to beat his cancer.

A member of a close-knit family, Amos is a sociable, spirited, great boy who loves to wrestle, ride his bike and swim.  He just celebrated his ninth birthday at a local pool.  In place of gift-giving, the family thought they could help make a difference.  Amos asked his friends to contribute to the National Foundation for Cancer Research in honor of his father’s successful battle with cancer.  He collected an impressive $130.00 that became $260.00 since it was received during the NFCR Matching Gift Campaign!

Amos, his parents and his little brother, Arlo, decided to donate to NFCR “since they research all types of cancers and they have a great reputation.”

Amos is proud to help fund NFCR because his father benefited so much from cancer research! Phil is doing very well now and gives credit to his doctors and his family.

NFCR salutes Amos for his generosity and compassion!  This generosity also says a lot about his family. The world needs more 9 year olds like Amos. What a wonderful family. What a wonderful heartfelt gift.

Please share this story – you can make a difference with this one simple act.  Use http://bit.ly/BeLikeAmos and spread the cheer. Also you can  Be like Amos and make a difference. Donate here. 

AN UPDATE: AUGUST 18, 2016BeLikeAmos cancer research screen capture 1000 views

With permission from Amos and his family, we shared this post on FaceBook and Twitter. Today, BeLikeAmos has now just exceeded ONE THOUSAND  views – making it one of the most popular posts at NFCR. With all the strife and shouting out there in the world ….isn’t it time for more of us to Be Like Amos- and quietly make a difference.Every voice and every donation – big and small – makes a difference. Thank you Amos and thanks family and friends and donors. By funding Cancer Research, you are helping to save lives!

Read more

Cancer Prevention for Asian American Women

NFCR President Sujuan Ba, Ph.D., delivered an address to the National Association of Professional Asian American Women (NAPAW) about the importance of cancer research and cancer prevention education.

cancer prevention and the logo of National Association of Professional Asian-American Women As an Asian American herself, Dr. Ba is acutely aware of the cancer risks in the Asian American women’s community.  She knows “there are many types of cancer that disproportionately affect women of Asian descent. Education and research are important tools that can provide a number of immediate solutions And, if if widely implemented, would go a long way towards reversing this trend.”  For more than 43 years, The National Foundation for Cancer Research has worked diligently in its mission to raise awareness, educate the public and financially support the work of cancer research scientists. NFCR helps insure translational medicine success. This bench to bedside approach is unique in American Cancer Charities. NFCR is among only a tiny handful of cancer research charities that funds chemists and lab scientists to put an end to all cancers.

The cause of and prevalence of cancer in Asian American women is believed to be both environmental and behavioral. Western diets, in particular, have been widely documented as a major contributing factor in increased cancer diagnoses. In the slideshow, you’ll find more information about cancer prevention tips, new cancer research and actions you can take to help prevent breast cancer, skin cancer, cervical cancer. There are also tips on how you can help prevent lung, prostrate and liver cancer. Men and women can benefit from the cancer prevention tips provided by NFCR and Dr. Sujuan Ba.

The statistics are staggering. Cancer is the number one killer of Asian American Women since 1980. Breast Cancer is the most commonly diagnosed cancer. Breast cancer is the second leading cause of cancer deaths. The incidence and death rates of liver cancer among all Asian Americans is twice as high as those among Caucasians. Liver cancer is the second leading cause of cancer deaths in Asian American men and the fifth leading cause of death among Asian American women.

Dr. Ba presented these slides as she gave a talk to the National Association of Professional Asian American Women’s meeting at the US Department of Health and Human Services, in Washington D.C. in June of 2016. For more information on ways you can support cancer research and to see the full range of educational and cancer research programs, visit www.NFCR.org

Click on the slide below to enlarge the presentation on cancer risks and prevention.

Read more

National Foundation for Cancer Research and KEW, Inc. announce a collaboration

National Foundation for Cancer Research and KEW, Inc. announce a collaboration to increase awareness of the value of genetic testing.

photo Tuan Ha-Ngoc, KEW & Franklin Salisbury NFCRBig Data comes to Cancer Care Choices.  #Research4aCure

BETHESDA, Maryland (June 8, 2016)  – The National Foundation for Cancer Research (NFCR) and Kew, Inc, a private oncology services company based in Cambridge, Massachusetts , announced today they will jointly work to increase the awareness of the clinical benefits of genetic testing to cancer patients and oncologists.  Precision medicine moves information faster to where the patient decisions are made, thereby potentially improving options, quality of care and potential outcomes as well.

The genetic testing technology, including Next-Gen Sequencing (NGS) on comprehensive and specific gene panels, is able to identify patient-specific drug targets and cancer-driving molecular pathways. Guided by the genetic testing results, oncologists can prescribe personalized and targeted cancer therapies to their patients.

With numerous new drugs that target specific cancer mutations in clinical trials, the ability to share information widely becomes an increasingly burdensome task. NFCR and KEW are teaming up to launch programs that aim to increase the awareness of the value of genetic testing, educate patients, family members and oncologists about the clinical benefits of testing and guide them through the seemingly complex clinical process in a much easier manner.

Raju Kucherlapati, MD, Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School and co-founder of KEW, spoke of the goal of “helping doctors everywhere, treat cancer patients anywhere.” “We are dedicated to empowering oncologists to make the right therapy decision for patients by providing actionable, patient-specific information derived from our genetic testing”, said Dr. Kucherlapati.

“KEW’s genetic testing technology and capability in bioinformatics will help to integrate data accumulated from various research and clinical sources into treatment options and cancer care choices, which is highly beneficial to cancer patients and in keeping with NFCR’s long valued efforts in sharing information among scientists, physicians and patients,” said NFCR Chief Science Officer, Michael Wang, MD, PhD.

Public outreach and education is one of the core missions of NFCR’s programs. For more than 43 years, NFCR has been supporting cancer research laboratories and then sharing results with oncologists, patients, and general public worldwide. Many of the NFCR-funded scientists have contributed to developing the foundation of today’s personalized targeted therapies and precision medicine.

NFCR welcomes KEW’s support of the education and communication facet of its mission. Together both organizations can help raise awareness of new options in cancer treatment.

NFCR is a convener and one of the early funders of applying genetic testing technology, including Next-Gen Sequencing (NGS) to clinical applications to guide personalized treatment for patients. With today’s internet speed of access, NFCR is taking fast actions to promote collaboration and information-sharing. NFCR is dedicated to supporting “high risk/high reward” cancer research and public education relating to prevention, early diagnosis, better treatments and, ultimately, a cure for all types of cancer.

For more information: www.nfcr.org; 301-654-1250

KEW, Inc. provides comprehensive genomic testing services that enable oncologists to make evidence-driven personalized treatment decisions for cancer patients. Based out of Cambridge, MA, KEW was founded by pioneers of the precision medicine industry, including key contributors to the Human Genome and The Cancer Genome Atlas projects. The CANCERPLEX® suite of products offers flexible panel sizes, the largest of which sequences 400+ cancer genes in solid tumors that are the most relevant to oncology patient care. Specialized panels offer the option to test based on the site of a patient’s tumor or to limit results to FDA-approved therapies. CANCERPLEX not only makes personalized medicine more accessible, it delivers the promise of precision medicine for all.

For more information: www.kewinc.com; 617-229-5954

KEW, Inc.
Mark D. Myslinski
Keith Spiro

Read more

NFCR Scientific Advisory Board

[et_pb_section admin_label=”section”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Intro Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]


The mission of the NFCR Scientific Advisory Board is to provide scientific, strategic, and clinical guidance and direction for NFCR basic science and translational research programs. Directed by Webster Cavenee, PhD, the NFCR Scientific Advisory Board is comprised of leaders in cancer research who have made significant breakthroughs in the diagnosis and treatment of cancer, scientists who are committed to furthering NFCR’s unwavering commitment to funding research that will cure cancer—all types of cancer.

The National Foundation for Cancer Research is an innovative cancer charity with a deep scientific base and a truly collaborative approach to cancer research reaching global dimensions. Research takes time and needs unwavering support. The path from a promising discovery to an effective treatment often takes a decade or more, and the NFCR Scientific Advisory Board will play a key role in guiding and prioritizing NFCR’s global research program, prioritizing the connections between basic and clinical research, translating discoveries in the laboratory into health benefits for patients—giving reason to hope in the progress being made against cancer—new treatments brought into the clinic, patients saved, and cures delivered.

“Research will cure cancer, and NFCR is about research,” said Sujuan Ba, PhD, NFCR President. “This Scientific Advisory Board will be about creating an environment that works to liberate science—an architecture for discovery, and the roadmap to new approaches for treating cancer.” This distinguished group will work closely with NFCR leadership to explore ways to accelerate the development successful treatments and ultimately a cure.

[/et_pb_text][et_pb_button admin_label=”Button” button_url=”http://nfcr.org/sabpress-release-2015-10-14/” url_new_window=”off” button_text=”View Press Release” button_alignment=”center” background_layout=”light” custom_button=”off” button_letter_spacing=”0″ button_use_icon=”default” button_icon_placement=”right” button_on_hover=”on” button_letter_spacing_hover=”0″] [/et_pb_button][et_pb_divider admin_label=”Divider” color=”#ffffff” show_divider=”on” divider_style=”solid” divider_position=”top” hide_on_mobile=”on” divider_weight=”5″] [/et_pb_divider][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]

Science Advisory Board Members

[/et_pb_text][et_pb_toggle admin_label=”Webster K. Cavenee (Director, Ludwig Institute for Cancer Research)” title=”Webster K. Cavenee (Director, Ludwig Institute for Cancer Research)” open=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]

web caveneeDr. Cavenee is a Professor of Medicine at the University of California at San Diego. Dr. Cavenee’s research is directed at defining the genetic lesions in human cancer, determining their physiological significance and using such information for therapeutic approaches.  His current interests include the malignant progression of astrocytic (brain) tumors, the role of DNA methylation in tumor initiation, the differentiation pathways of astrocytes and the role of fusion transcription factors in pediatric neoplasms.

Dr. Cavenee received his Ph.D. with honors in 1977 from the University of Kansas Medical School and then did postdoctoral work at the Jackson Laboratory, MIT and the University of Utah.  He held faculty positions at the University of Cincinnati and McGill University.  Since 1991, he has been the Director of the Ludwig Institute for Cancer Research and Distinguished Professor of Medicine at the University of California at San Diego.

Dr. Cavenee is a member of the National Academy of Sciences and the Institute of Medicine and he is a Past-President of the American Association for Cancer Research, a Fellow of the American Academy of Microbiology, a Fellow of the International Union Against Cancer and an elected member of the American Society for Clinical Investigation.  He serves on the editorial boards of several journals as well as the scientific advisory boards of several companies and private foundations and has also served on the Boards of Scientific Counselors of the National Cancer Institute and the National Institute of Environmental Health Sciences.  He has published over 300 scientific papers and received more than 80 honors, most notably the Rhoads Award of the American Association for Cancer Research, the Charles S. Mott Prize of the General Motors Cancer Research Foundation and the Albert Szent-Gyorgyi Award from the National Foundation for Cancer Research.

[/et_pb_toggle][et_pb_toggle admin_label=”Peter Vogt (Professor, Scripps Research Institute)” title=”Peter Vogt (Professor, Scripps Research Institute)” open=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]

vogtPeter K. Vogt is an American molecular biologist, virologist and geneticist. His research focuses on retroviruses and viral and cellular oncogenes.

Vogt received his undergraduate education in biology at the University of Würzburg and in 1959 was awarded his Ph.D. at the University of Tübingen for work done at the Max Planck Institute for Virology in Tübingen. From 1959 to 1962 he was Damon Runyon Cancer Research Fellow in the laboratory of Harry Rubin at the University of California in Berkeley and started work on Rous sarcoma virus. He taught microbiology and molecular biology to medical and graduate students at the University of Colorado in Denver (1962–1967) and the University of Washington in Seattle (1967–1971). In 1971, he joined the University of Southern California as Hastings Professor of Microbiology and in 1980 assumed the chairmanship of the Department of Microbiology at the School of Medicine. Since 1993, he has been a Professor at The Scripps Research Institute in La Jolla. He became Executive Vice President and Chief Scientific Officer at Scripps in 2012.

At the beginning of his scientific career, Vogt studied mechanisms of retroviral cell entry and the role of viral surface proteins in determining host range. He defined related groups of viral surface proteins and their corresponding receptors on the cell surface. During his time in Seattle, his focus shifted to the genetics of retroviruses. Together with his associate Kumao Toyoshima, he isolated the first temperature sensitive mutants of a retrovirus and in collaboration with the biochemist Peter Duesberg discovered the first retroviral oncogene, src. His work on mutants of the Rous sarcoma virus enabled Michael Bishop and Harold Varmus to isolate DNA sequences that represent the src oncogene and to demonstrate the cellular origin of oncogenes. In his extensive studies on avian retroviruses, Vogt discovered oncogenes that play important roles in human cancers, e.g. myc (in collaboration with Bister and Duesberg), jun (with Maki and Bos) and p3k (with Chang).

Vogt has received the Irene Vogeler Prize (1976),[citation needed] the Alexander von Humboldt Award (1984),[citation needed] the Ernst Jung Prize for Medicine (1985),[citation needed] the Robert J. and Claire Pasarow Award (1987),[citation needed] the Paul Ehrlich and Ludwig Darmstaedter Prize (1988),[citation needed] the Bristol Myers Award (1989),[citation needed] the Charles S. Mott Prize (1991)[citation needed] and the Albert Szent Györgyi Prize (2010). He holds an honorary doctorate from the University of Würzburg (since 1995) and has been elected to several academies, including the National Academy of Sciences USA, the American Philosophical Society, the American Academy of Arts and Sciences, the German National Academy of Sciences Leopoldina and the American Academy of Microbiology.[citation needed] He is on several scientific advisory and editorial boards, e. g. the Sidney Kimmel Foundation for Cancer Research (since 2005),[citation needed] the Proceedings of the National Academy of Sciences, USA (since 2000) and Current Topics in Microbiology and Immunology (since 1967).

[/et_pb_toggle][et_pb_toggle admin_label=”Frederick W. Alt (Professor, Harvard Medical School)” title=”Frederick W. Alt (Professor, Harvard Medical School)” open=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]

2_Alt_FrederickDr. Frederick Alt is currently the Director of the Program in Cellular and Molecular Medicine (formerly the Immune Disease Institute) at Boston Children’s Hospital. Dr. Alt has been Professor of Genetics at Harvard Medical School since 1991 and Charles A. Janeway Professor of Pediatrics at Boston Children’s Hospital since 1993. Prior to 1991, Dr. Alt was on the faculty at Columbia University. He earned his Ph.D. with distinction from the Stanford University Department of Biological Sciences in 1977. Dr. Alt is a member of the National Academy of Sciences, the Institute of Medicine of the National Academies, and a fellow of the American Academy of Arts and Sciences, the American Academy of Microbiology, and the American Association for the Advancement of Science. He is also an Investigator with the Howard Hughes Medical Institute.

Dr. Alt has won numerous honors for biomedical research including the Stanford University Medical Center Arthur Kornberg and Paul Berg Lifetime Achievement Award in Biomedical Science, and the National Cancer Institute’s Alfred Knudson Award for “Pioneering contributions that have revolutionized the field of cancer genetics.” Each year the Cancer Research Institute of New York presents the Frederick W. Alt Award for New Discoveries in Cancer Immunology in his honor. Dr. Alt’s impact extends far beyond his own laboratory, for not only is he an outstanding researcher; he is also an exemplary teacher. In 2003 he received the American Association of Immunologists Excellence in Mentoring Award. Dr. Alt has mentored over 100 students and research fellows, many of whom have become leaders in immunology, genetics, or cancer biology.

[/et_pb_toggle][et_pb_toggle admin_label=”Kanaga Sabapathy (Scientific Director, National Cancer Center, Singapore)” title=”Kanaga Sabapathy (Scientific Director, National Cancer Center, Singapore)” open=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]

kangaKanaga Sabapathy obtained his B.Sc (Hons) degree in Zoology from the NUS, and then his Ph.D. in Molecular & Cellular Immunology from the IMCB, Singapore, in 1995. His post-doctoral work was conducted at the Institute of Molecular Pathology in Vienna with Dr Erwin Wagner, studying the c-Jun-N-terminal kinase stress signaling pathway, using genetically-engineered mice. He moved to the National Cancer Centre Singapore (NCCS) in late 1999 as the Principal Investigator of the Laboratory of Molecular Carcinogenesis, and since 2013, is the overall Head of the Division of Cellular & Molecular Research, overseeing NCCS’ research activities.

He is also the Research Director of the Academic Clinical Program in Oncology at SingHealth. Dr Sabapathy is a Professor with the Cancer and Stem Cell Biology Program at Duke-NUS; a joint Professor with the Department of Biochemistry at NUS and a joint Research Director at the IMCB. Dr Sabapathy is a Fellow to the Royal College of Pathologists (UK), and was recently awarded the inaugural National Research Foundation Investigatorship award (Class of 2015) in recognition of his work, to further his investigations on ground-breaking, high-risk research.

[/et_pb_toggle][et_pb_toggle admin_label=”Ruggero De Maria (Director, Regina Elena Cancer Center, Rome)” title=”Ruggero De Maria (Director, Regina Elena Cancer Center, Rome)” open=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]

De MariaRuggero De Maria graduated in Medicine in 1989 and specialized in Endocrinology in 1994. Dr. De Maria has been Scientific Director of the Regina Elena National Cancer Institute (Rome, Italy) since November 2011. He was appointed this position by the Italian Minister of Health for a five year term. His main effort is to create a productive synergy between basic and clinical research. Throughout the years, Dr. De Maria has gained international recognition for his research activity on cancer stem cells (CSCs), a rare population of cells responsible for tumor initiation and growth. During his term as Head of the Department of Hematology, Oncology and Molecular Medicine at the National Institute of Health, Rome (Istituto Superiore di Sanità) from 2008 to 2011 his research team was the first to isolate CSCs from colon and lung cancers and develop innovative CSC-based preclinical models of these tumors.

Moreover, he has published several seminal articles on glioblastoma stem cells. De Maria’s current research programs are centred on the molecular characterization of CSCs with the aim of discovering innovative biomarkers and molecular targets to improve cancer management and develop novel cancer therapies. Other research interests comprise the study of microRNA and the microenvironment in solid tumors. From this year 2013, De Maria has also been appointed President of the Italian ACC Association (Alleanza Contro il Cancro/Alliance in the fight against Cancer) until 2018. He currently holds several Editorial Board positions on internationally renowned scientific journals such as Cell Death and Disease; Oncogene; Cell Death and Differentiation. He has published over 140 original peer-reviewed scientific articles and reviews in the most important journals including Nature; Science; Nat Med; Nat Immunal; J Exp Med. De Maria also sits on various prestigious Advisory Board Committees such as the Pezcoller Foundation AACR International Award, AACR INNOVATOR Award, Veronesi Foundation, AIRC and InBev-BAILLET LATOUR Health Prize.


Read more

Erik’s 50th Marathon


erik sugar 3

Erik Seastead

Erik Seastead died on March 24, 2016, after a three-month battle with glioblastoma, among the most aggressive and deadly forms of brain cancer. We’ll miss his kindness and his love. He was a family man. He was a loving husband. He was a runner, and he was our runner. He belonged to the Old Man and Cop track club.  He was its leader, and it is our mission to honor him through this fundraiser.

Erik's Medals

Erik’s medal collection


The Old Man and Cop track club gathered almost weekly, on Saturday mornings, at 7 am, no matter the weather, the ice and snow, the humid summer days, for long training runs in preparation for the next marathon. During that time we talked about many things, so many things we can’t remember.  But Erik was our leader through all  of the discussions, and he was also a great listener.  We we were best friends, and best friends live forever.

At Erik’s funeral, a minister spoke, as did friends and family. I read from our own Runner’s Psalter, the Book of Marathon. It was meant to show Erik’s joy for life, his leadership, his love of others.

Please remember: Erik will take us on his next run, his 50th marathon, at Sugarloaf, Maine, in May 2016. We are warmed to know that not only he, but some of you will be on the course that day to greet us.

Now we celebrate our friendship with Erik by asking you to support research on glioblastoma with a donation of $10, $25, $50, $100.  For Erik’s memory we would love to achieve our goal of $30,000. Can you give something now?

Paul Josephson

Marathon runner, Friend of Erik

Support Erik’s 50th and Help End Glioblastoma

Erik Seastead, Steve Saunders, Paul Josephson, Jon Chapin:  the Old Man Track Club, before Sugarloaf Marathon 2002.

Check out the Erik’s 50th Marathon team on the Pace Per Mile podcast!


Read more